What this is
- How it works
- How it works isn't classified yet
- Tested for
- Autism Spectrum Disorder
- Main trialPhase 2
- “ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have completed study ML-004-002. The primary objective of the study will be to evaluate the safety of ML-004 in subjects with ASD.”In the company’s words, NCT05889273 on ClinicalTrials.gov
Other drugs for Autism Spectrum Disorder
- CM-ATCuremark · Phase 3
- NTI164Fenix Innovation Group · Phase 3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- Terpenes-Enriched CBD-Predominant OilBazelet Nehushtan LtD. · Phase 2
Coming up1
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Nov 2027 | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | |
| Phase 2Completed | 10 Mar 2026 | ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026